Back to All Events

Learnings from Agomab's recent $208m NASDAQ IPO

With David Epstein.

Previous
Previous
5 March

Board Chair perspectives on Agomab's $200m NASDAQ IPO

Next
Next
27 May

China as a Board-level Conversation: How to evaluate, diligence and execute